Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | IL2 | P60568 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29865935 | 0.84 | CSNK2A1 (0.57) | ALDH1A1KDM4EHSD17B10MAPTL3MBTL1 | |
| SCHEMBL27512420 | 0.84 | CSNK2A1 (0.57) | ALDH1A1KDM4EHSD17B10MAPTL3MBTL1 | |
| SCHEMBL7703619 | 0.84 | ALB (0.44) | ALDH1A1KDM4EHSD17B10POLBMAPT | |
| SCHEMBL18313718 | 0.83 | KDM4E (0.54) | ALDH1A1KDM4EHSD17B10POLBMAPT | |
| SCHEMBL20558990 | 0.82 | KDM4E (0.48) | ALDH1A1KDM4EHSD17B10MAPTKMT2A | |
| SCHEMBL5584152 | 0.81 | KDM4E (0.65) | ALDH1A1KDM4EHSD17B10POLBMAPT | |
| SCHEMBL21951007 | 0.79 | KDM4E (0.54) | ALDH1A1KDM4EHSD17B10POLBMAPT | |
| SCHEMBL16708127 | 0.79 | ALB (0.44) | ALDH1A1KDM4EHSD17B10POLBMAPT | |
| SCHEMBL16693136 | 0.79 | MAOB (0.53) | ALDH1A1KDM4EHSD17B10MAPTKMT2A | |
| SCHEMBL31723089 | 0.78 | ALB (0.41) | ALDH1A1KDM4EHSD17B10POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802927-B2 | Oxadiazine compounds and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802927-B2 | Oxadiazine compounds and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802927-B2 | Oxadiazine compounds and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170066753-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS, INC. | 2017-03-09 | — | — | US | disclosed |
| US-20170066753-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS, INC. | 2017-03-09 | — | — | US | disclosed |
| US-20170066753-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS, INC. | 2017-03-09 | — | — | US | disclosed |
| WO-2016201168-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | FORUM PHARMCEUTICALS INC. (US) | 2016-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066753-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | PSEN2, SMN1; SMN2, OTC | ALDH1A1 1137/4885KDM4E 3178/4885HSD17B10 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.